TABLE 3.

Adverse events and their management recorded during the treatment period

	Complete cohort	Pirfenidone	Nintedanib
Type of adverse events	30	14	16
Photosensitivity	3 (10)	3 (21.4)	0 (0)
Diarrhoea	7# (23.3)	0 (0)	9# (56.3)
Liver toxicity	0 (0)	0 (0)	0 (0)
Bleeding	0 (0)	0 (0)	0 (0)
Gastrointestinal upset	4 (13.3)	1 (7.1)	3 (18.8)
Fatigue	3 (10)	1 (7.1)	2 (12.5)
Death	5¶ (16.7)	2 (14.3)	3 (18.8)
Management of adverse events
Symptomatic management	3 (12)	0 (0)	5 (31.3)
Dose reduction	5 (20)	1 (7.1)	4# (25)
Drug discontinuation	5 (20)	3 (21.4)	2 (12.5)
Switch to alternative antifibrotic	4 (16)	3 (21.4)	1 (6.3)

Data are presented as n or n (%). ^#: one patient switched from pirfenidone to nintedanib experienced diarrhoea which was managed with dose reduction; ^¶: death occurred in one patient switched from pirfenidone to nintedanib and in one patient switched from nintedanib to pirfenidone.